Estrogen and progesterone receptors in endometrial cancer: Clinicopathological correlations and prognostic significance

APMIS, Supplement

Volumn 104, Issue 65, 1996, Pages 5-33

  Nyholm, Henrik Christian Juul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; CARCINOMA; CHEMISTRY; ENDOMETRIUM TUMOR; PATHOLOGY;

CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030332944     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.1996.tb05585.x     Document Type: Article

References (183)

1. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093-103.
2. Andersen J, Bentzen SM, Poulsen HS. Relationship between radioligand binding assay, immmunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol 1988;24:377-84.
3. Andersen J. Determination of estrogen receptors in paraffin-embedded tissue. Acta Oncol 1992;31:611-27.
4. Announcements. FIGO Stages-1988 Revision. Gynecol Oncol 1989;35:125-7.
5. Antunes CMF, Stolley PD, Rosenshein NB, Davies JL, Toriascia JA, Brown C, Burnett L, Rutledge A, Polkempner M, Garcia R. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.
6. Armstrong BK, Doll R. Environmental factors and cancer incidence and mortality in different countries with special reference to dietary practices. Int J Cancer 1975;15:617-31.
7. Austin H, Austin JM, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991;51:568-72.
8. Ayhari A, Yarali H, Ayhan A. Endometrial carcinoma: A pathologic evaluation of 142 cases with and without associated endometrial hyperplasia. J Surg Oncol 1991;46:182-4.
9. Badawy SZ, Elliott LT, Elbadawy A, Marshall LD. Plasma levels of oestrone and oestradiol-17beta in postmenopausal women. Br J Obstet Gynaecol 1979;86:56-63.
10. Baulieu EE, Robel P, Mortel R, Levy C. Estrogen and progesterone receptors in postmenopausal endometrial carcinoma: the potential of a dynamic test using tamoxifen. In Steroids and Endometrial Cancer, Jasonni VM (ed), Raven Press, New York 1983:61-68.
11. Bayard F, Damilano S, Robel P, Baulieu E-E. Cytoplasmic and nuclear estradiol and progesterone receptors in human endometrium. J Clin Endocrinol Metab 1978;46:635-48.
12. Benjamin F, Deutsch S. Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma. Am J Obstet Gynecol 1976;126:638-47.
13. Benraad THJ, Friberg LG, Koenders AJM, Kullander I. Do oestrogen and progesterone receptors in metastasizing endometrial cancers predict the response to progestagen therapy? Acta Obstet Gynecol Scand 1980;59:155-9.
14. Bergeron C, Ferenczy A, Shyamala G. Distribution of estrogen receptors in vaious cell types of normal, hyperplastic, and neoplastic human endometrial tissues. Lab Invest 1988;58:338-45.
15. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
16. Brody S, Carlstrom K, von Uexkull A-K, Lagrelius A, Lunell N-O, Rosenborg L. Peripheral hormone levels and the endometrial condition in postmenopausal women. Acta Obstet Gynecol Scand 1983;62:525-9.
17. Bruning PF, Bonfrer J M. Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma. Cancer Res 1986;46:2606-11.
18. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr. Immunohistochemical analysis of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986,46:5419-25.
19. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990;94:247-54.
20. Carlson JA, Allegra JC, Day TG, Wittliff JL. Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 1984;149:149-53.
21. Carlstrom K, von Uexkull A-K, Einhorn N, Fredricsson B, Lunell N-O, Sundelin P. Metabolism of estrone sulphate in human endometrium. Acta Obstet Gynecol Scand 1983;62:519-24.
22. Cavanagh D, Maesden DE, Ruffolo EH. Carcinoma of the endometrium. Obstet Gynecol Ann 1984;13:211-60.
23. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988;31:65-77.
24. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990;94:255-60.
25. Charpin C, Martin PM, Lavaut MN, Porreau-Schneider N, Toga M. Estrogen receptor immunocytochemical assay (ER-ICA) in human endometrium. Int J Gynecol Pathol 1986;5:119-31.
26. Criristopherson WM. The significance of the pathologic findings in endometrial cancer. Clin Obstet Gynaecol 1986;13:673-93.
27. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2:1102-9.
28. Clark JH, Peck Jr EJ. Nuclear retention of receptor-estrogen complex and nuclear acceptor sites. Nature 1976;260:635-7.
29. Clark JH, Peck Jr EJ, Hardin J W, Eriksson H. The biology and pharmacology of estrogen receptor binding: Relationship to uterine growth. In: O'Malley BW, Birnbaumer L, eds. Receptors and hormone action II. London, Academic Press 1978:1-31.
30. Clark JH, Schrader WT, O'Malley BW. Mechanisms of action of steroid hormones. In: Williams Textbook of Endocrinology, eds. Wilson & Foster. WB Saunders 1992, pp 35-90.
31. Clemmensen IH, Storm HH. Kræft i Danmark, en opslagsbog. Kobenhavn: Kræftens Bekæmpelse 1993.
32. Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium: III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1982;59:569-75.
33. Creasman WT, McCarthy K Sr, Barton TK, McCarthy K Jr. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980;55:363-70.
34. Creasman WT, Soper JT, McCarty K Jr, McCarty K Sr, Hinshaw W, Clarke-Pearson DL. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial cancer. Am J Obstet Gynecol 1985;151:922-32.
35. Cullen TS. Cancer of the uterus. New York, D. Appleton and Co. 1900.
36. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5.
37. Deligdisch L, Holinka CF. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986; 57: 1385-8.
38. Demopoulos RI, Dubin N, Noumoff J, Blaustein A, Sommers GM. Prognostic significance of squamous differentiation in stage I endometrial adenocarcinoma. Obstet Gynecol 1986;68:245-50.
39. DeSombre ER, Thorpe SM, Rose C, Blough RR, Andersen KW, Rasmussen BB, King WJ. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 1986 (Suppl);46:4256-64
40. Devesa SS, Silverman DT, Young JL Jr, Pollack ES, Broen CC, Horm JW, Percy CL, Myers MH, McKay FW, Fraumeni JF Jr. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987;79:701-70.
41. Ehrlich CE, Young PCM, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications.Am J obstet Gynecol 1981;141:539-46.
42. Ehrlich CE, Young PCM, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
43. Elwood M, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977;59:1055-60.
44. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement treatment. Maturitas 1988;10:271-82.
45. Fernoe M, Borg A, Horvath G, Lindahl B. Enzyme immunoassay of progesterone receptor in cancerous and normal endometrial tissue. A comparison with dextran coated charcoal method. Anticanc Res 1989;9:1681-4.
46. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20.
47. Gambrell RD. The role of hormones in the etiology and prevention of endometrial cancer. Clin Obstet Gynecol 1986a;13:695-723.
48. Gambrell RD. Prevention of endometrial cancer with progestins. Maturitas 1986b;8:159-68.
49. Gelfand MM, Ferenczy A. A prospective 1-year study of oestrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74:398-402.
50. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial carcinoma: A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986;58:1518-25.
51. Gray LA, Christopherson WM, Hoower R. Estrogens and endometrial cancer. Obstet Gynecol 1977;49:385-9.
52. Greene GL. Application of immunochemical techniques to the analysis of estrogen receptor structure and function. Biochemical actions of hormones. New York: Academic Pres Inc., 1984;11:207-39.
53. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231:1150-4.
54. Greene GL, Press MF. Structure and dynamics of the estrogen receptor. J Steroid Biochem 1986;24:1-7.
55. Greene GL, Press MF. Application of monoclonal antibodies against estrogen and progesterone receptors in the immunocytochemical evaluation of breast carcinomas. In: Cariani RL, ed. Immunological approaches to the diagnosis and therapy of breast cancer. New York, Plenum Publishing Corp. 1987.
56. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Endocrinol Metab 1973;36:207-14.
57. Gurpide E, Blumenthal R, Fleming H. Regulation of estrogen receptor levels in endometrial cancer cells.In: Hormones and Cancer pg. 145-65, 1984. Ed. Alan R. Liss,Inc, NewYork, NY 10011.
58. Gusberg SB. The individual at high-risk for endometrial carcinoma. Am J Obstet Gynecol 1976;126:535-42.
59. Heubner A, Beck T, Grill H-J, Pollow K. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor enzyme immunoassay, and radioligand-labelled estrogen receptor assay in human breast cancer and uterine tissue. Cancer Res 1986;46:4191s-5s.
60. Hoogerland DL, Buchler DA, Crowley JJ, Carr WF. Estrogen use: Risk of endometrial cancer. Gynecol Oncol 1978;6:451-8.
61. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting a response to endocrine therapy in human breast cancer: a hypothesis. Science 1975;189:726-7.
62. Horwitz RI, Feinstein AR. Alternative analytical methods for case-control studies of estrogens and endometrial cancer. N Eng J Med 1978;299:1089-94.
63. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J BiolChem 1978;253:2223-8.
64. Hunt K, Vessey M, Pherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35.
65. Hunter RE, Longcope C, Jordan VC. Steroid hormone receptors in adenocarcinoma of the endometrium. Gynecol Oncol 1980;10:162-61.
66. Ingram SS, Rosenmann J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 1989;17:21-7.
67. Janne O, Kaupilla A, Kontula K, Syrjala P, Vihko R. Female steroid hormone receptors in normal, hyperplastic and carcinomatous endometrium. the relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration. Int J Cancer 1979;24:545-54.
68. Jensen EV, Greene GL, Closs LE, DeSombre ER, Nadji M. Receptors considered. A 20-year perspective. Rec Prog Horm Res 1982;38:1-40.
69. Jordan VC, Jacobsen HI, Keenan EJ. Determination of estrogen receptors in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. Cancer Res (Suppl) 1986;46:4237s-40s.
70. Judd H, Davidson B, Frumar A, Lagasse L, Ballon S. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gyneco!1980;1367:859-71.
71. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993;50:281-6.
72. Kastner P, Krust A, Turcotte B, Stropp U, Tora I, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-14.
73. Kauppila A, Kujansuu E, Vihko R. Cytosol estrogen and progesterone receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestins. Cancer 1982a;50:2157-62.
74. Kauppila A, Gronroos M, Nieminen U. Clinical outcome in endometrial cancer. Obstet Gynecol 1982b;60:473-80.
75. Kauppila A, Janne O, Stenback F, Vihko R. Cytosolic estrogen and progestin receptors in human endometrium from different regions of the uterus. Gynecol Oncol 1982c;14:225-9.
76. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. Acta Obstet Gynecol Scand 1984;63:441-50.
77. Kauppila A, Isotalo HE, Kivinen ST, Vihko R. Prediction of clinical outcome with estrogen and progestin receptor concentration and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 1986;46:5380-4.
78. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. Acta Oncol 1989;28:561-6.
79. King RJB, Townsend PT, Siddle N, Whitehead MI, Taylor RW. Regulation of estrogen and progesterone receptor levels in epithelium and stroma from pre- and postmenopausal endometria. J Ster Biochem 1982;16:21-9.
80. King WJ, DeSombre ER, Jensen EV, Greene GL. Comparison of cytochemical and steroid-binding assays for estrogen receptor in human breast cancer. Cancer Res 1985;37:4669-71
81. Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990;38:59-65.
82. Koenders A, Thorpe SM, on behalf of the EORTC receptor group: Standardization of steroid receptor assays in human breast cancer. IV. Long-term intra- and inter-laboratory variance analysis of estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol 1986;22:945-52.
83. Korenman SG, Perrin LE, McCallum TP. A radio-ligand binding assay system for estradiol measurement in human plasma. J Clin Endocrinol 1968;29:879-83.
84. Kreitmann B, Bugat R, Bayard F. Estrogen and proegsterone regulation of the progesterone receptor concentration in human endometrium. J Clin Endocrinol Metab 1979;49:926-9.
85. Leather AT, Sawas M, Studd JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991;78:1008-10.
86. Leclercq G, Bojar H, Goussard J, Nicholson RA, Pichon MF, Piffanelli A, Poussette A, Thorpe SM, Lonsdorfer M. Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer. A European multicenter study. Cancer Res 1986 (Suppl); 46:4233-6.
87. Le Marchand L, Wilkens LR, MI M-P. Early-age body size, adult weight gain and endometrial cancer risk. Int J Cancer 1991;48:807-11.
88. Lessey BA, Killam AP, Metzger DA, Haney AF, Green GL, McCarty S J r. Immunohistochemical analysis of human estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988;67:334-40.
89. Levy C, Robel P, Gautray JP, de Brux J, Verma U, Descomps B, Baulieu EE. Estradiol and progesterone receptors in human endometrium: Normal and abnormal menstrual cycles and early pregnancy. Am J Obstet Gynecol 1980;136:646-51.
90. Liao BS, Twiggs LB, Leung BS, Yu WCY, Polish RA, Prem KA. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial cancer. Obstet Gynecol 1986;67:463-7.
91. Lindahl B, Ahn P, Ferno M, Norgren A, Trope C. Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma. Am J Obstet Gynecol 1984;149:607-12.
92. Lindahl B, Aim P, Ferno M, Grundsell H, Norgren A, Trope C. Relapse of endometrial carcinoma related to steroid receptor concentration, staging, histologic grading and myometrial invasion. Anticancer Res 1986;6:1317-20.
93. L'Hermite M. Risks of estrogens and progestogens. Maturitas 1990;12:215-46.
94. Lobo RA, Whitehead M. Too much of a good thing? Use of progestogens in the menopause: an international consensus statement. Fertil Steril 1989;51:229-31.
95. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to oestrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978;1304:448-55.
96. MacMahon B. Risk factors for endometrial cancer. Gynecol Oncol 1974;2:122-9.
97. Marchal S, Marchal C, Hoffstetter S, Parache RM, Pernot M. Determination of estrogen and progesterone receptors in endometrial adenocarcinomas. Comparison between dextran-coated charcoal and immunoenzymatic methods on curettage biopsies. Anticanc Res 1992;12:1307-10.
98. Martin PM, Rolland PH, Gammerre M, Serment H, Toga M. Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer 1979;23:321-9.
99. Martin JD, Hahnel R, McCartney AJ, Woodings TL. The effect of estrogen receptor status on survival in patients with endometrial cancer. Am J Obstet Gynecol 1983;147:322-4.
100. McCarty K Jr, Barton TK, Fetter BF, Creasman WT, McCarty K Sr. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol 1979;96:171-83.
101. McCarty Jr KS, Miller LS, Cox EB, Conrath J, McCarty Sr KS. Estrogen receptor analysis. Correlation of biochemical and immunohistochemical methods using monoclonal anti-receptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
102. McGuire WL. Steroid hormone receptors and disease: breast cancer. Proc Soc Exp Biol Med. 1979;162:22-5.
103. McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577,1991.
104. Meldrum DR, Davidson BJ, Tataryn I, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981;57:624-8.
105. Misrahi M, Atger M, d'Auriol L, Loosfelt H, Meriel C, Fridlansky F, Guiochon-Mantel A, Galibert F, Milgrom E. Complete amino acid sequence of the progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun 1987;143:740-8.
106. Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hannah WM. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol 1987;23:819-26.
107. Mortel R, Levy C, Wolff JP, Nicolas JC, Robel P, Baulieu EE. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res 1981;41:1140-7.
108. Mortel R, Zaino R, Satyawaroop PG. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer 1984;53:113-6.
109. Mutch DG, Soper JT, Budwit-Novotny DA, Cox EB, Creasman WT, McCarty KS Sr, McCarty KS Jr. Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol 1987;157:924-31.
110. Namkung PC, Moe RE, Petra PH. Stability of estrogen receptors in frozen human breast tumor tissue. Cancer Res 1979;39:1124-5.
111. Nardone FC, Benedetto MT, Rossiello F, Bongiorno M, Iacobelli S, Mancuso S, Dell'Acqua S. Hormone receptor status in human endometrial adenocarcinoma. Cancer 1989;64:2572-8.
112. Neumannova M, Kauppila A, Vihko R. Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium. Obstet Gynecol 1983;61:181-8.
113. Neumannova M, Kauppila A, Kivinen S, Vihko R. Short-term effects of tamoxifen, medroxyprogesterone acetate and their combination on cytosol and nuclear estrogen and progestin receptor concentrations and 17beta-hydroxysteroid dehydrogenase activity in normal human endometrium. Obstet Gynecol 1985;66:695-700.
114. Nisker JA, Hammond GL, Davidsson BJ, Frumar AM, Takaki NK, Judd HL, Siiteri PK. Serum sex hormone binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. Am J Obstet Gynecol 1980;138:637-42.
115. Nyholm HCJ, Djursing H, Hagen C, Agner T, Bennett P, Svenstrup B. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab 1989,69:946-9.
116. Nyholm HCJ. Endometriecancer og steroidhormonreceptorer. Ugeskr Læg 1990;152:593-7.
117. Nyholm HCJ, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: Correlations with stage and other clinicopathologic features. Am J Obstet Gynecol 1992;167:1334-42.
118. Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Thorpe SM. Estrogen and progesterone receptors in endometrial carcinoma: Comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol 1993a;12:246-52.
119. Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993b;100:1115-9.
120. Nyholm HCJ, Nielsen AL, Lyndrup J, Thorpe SM. Progesterone receptor content in endometrial carcinoma correlates with serum levels of free estradiol. Acta Obstet Gynecol Scand 1993c;72:565-9.
121. Nyholm HCJ, Nielsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: Comparison of clinical and histopathological characteristics. Gynecol Oncol 1993d;49:229-35.
122. Nyholm HCJ, Nielsen AL, Lyndrup J, Greene GL, Thorpe SM. Estrogen receptor determination in endometrial carcinoma: ligand binding versus enzyme-immunoassay methods. Anticancer Res 1995a;15:649-54.
123. Nyholm HCJ, Christensen I J, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995b;59:347-51.
124. O'Connell M, McDonnell L, Duffy MJ. Studies on nuclear estradiol receptors in human mammary carcinoma. Clin Chim Acta 1982;119:285-9.
125. Ohno Y, Fujibayashi H, Kitagawa I, Fujimoto Y, Okada H. Medroxyprogesterone acetate binding sites in human endometrium and endometrial cancer. Gynecol Obstet Invest 1990;29:227-31.
126. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of estrogen replacement therapy: A cohort study. Br J Cancer 1989;59:445-7.
127. Palmer DC, Muir IM, Alexander AI, Cauchi M, Bennett RC, Quinn MA. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1988;72:388-93.
128. Parazzini F, La Vecchia Carlo, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991;164:522-7.
129. Petterson B, Bergstrom R, Johansson E. Serum estrogens and androgens in women with endometrial cancer. Gynecol Oncol 1986;25:223-233.
130. Persson I. The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies. Acta Obstet Gynecol Scand 1985;130(suppl):59-66.
131. Persson I, Adami H-O, Bergkvist L, Lingren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Bj Med J 1989;298:147-51.
132. Pfeffer U, Fecarotta E, Castagnetta L, Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human cancer cell lines. Cancer Res 53:741-43, 1993.
133. Pollow K, Lubbert H, Boquoi E, Kreuzer G, Pollow B. Characterization and comparison of receptors for 17beta estradiol in human proliferative endometrium and endometrial carcinoma. Endocrinology 1975;96:319-28.
134. Pollow K, Manz B, Grill JH. Estrogen and progesterone receptors in endometrial cancer. In: Jasonni VM (Ed) Steroids and Endometrial Cancer. New York: Raven Press 1983:33-60.
135. Pollow K, Heubner A, Grill HJ, Beck T, Manz B. Present problems of steroid hormone receptors analysis in the tumor tissue. In: Schulz KD, King RJB, Pollow K, Taylor RW, eds. Endometrial cancer. Symposium. Marburg, 1986. Munchen: Zuckschwerdt Verlag, 1987:52-66.
136. Press MF, Nousek-Goebl NA, Bur M, Greene GL. Estrogen receptor localization in the female genital tract. Am J Pathol 1986;123:280-92.
137. Press MF, Udove JA, Greene GL. Progesterone receptor distribution in the human endometrium. Am J Pathol 1988;131:112-24.
138. Punnonen R, Kouvonen I, Lovgren T, Rauramo L. Uterine and ovarian estrogen receptor levels in climacteric women. Acta Obstet Gynecol 1979;58:389-91.
139. Quinn MA, Pearce P, Fortune DW, Koh SH, Hsieh C, Cauchi M. Correlation between cytoplasmic steroid receptors and tumour differentiation and invasion in endometrial carcinoma. Br J Obstet Gynaecol 1985a;92:399-406.
140. Quinn MA, Cauchi M, Fortune D. Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 1985b;21:314-9.
141. Quinn MA. Steroid receptors and gynaecological cancer. Prog Obstet Gynaecol 1988;7:331-53.
142. Ravn V, Rasmussen BB, Hojholt L, Barfoed M, Heiberg I, Svenstrup B, Thorpe SM. Estrogen and progesterone receptors in normal cycling endometrium as studied by end-point titration. Cell Tissue Res 1994;276:419-28.
143. Robboy S J, Bradley R. Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 1979;54:269-77.
144. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148-52.
145. Runowicz CD, Nuctern LM, Braunstein JD, Jones JG. Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol Oncol 1990;38:437-41.
146. Satyaswaroop PG, Zaino R, Clarke CL, Mortel R. Nude mouse system in the study of tumour biology, treatment, strategies and progesterone receptor physiology in human endometrial cancer. J Steroid Biochem 1987;27:431-8.
147. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-72.
148. Scharl A, Vierbuchen M, Graupner J, Fischer R, Bolte A. Immunohistochemical study of distribution of estrogen receptors in corpus and cervix uteri. Arch Gynecol Obstet 1988;241:221-33.
149. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982;37:79-82.
150. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS. Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 1989;73:780-5.
151. Shanklin DR. Endometrial carcinoma, diagnostic criteria, pathogenesis, natural history, and associations. Pathol Ann 1978;13:233-87.
152. Shapiro S, Kelly JP, Rosenberg L. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. New Eng J Med 1985;313:969-72.
153. Siiteri PK, Schwartz BE, MacDonald PC. Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer. Gynecol Oncol 1974;2:228-38.
154. Siterii PK. Receptor binding studies (letter). Science 1984;223:191-3.
155. Silverberg E, Lubera JA. Cancer Statistics 1989. CA 1989;39:3-20.
156. Silverberg SG, Mullen D, Faraci JA, Makowski EL, Miller A, Finch JL, Sutherland JV. Endometrial carcinoma: Clinico-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous estrogens. Cancer 1980;45:3018-26.
157. Slaga TJ. Mechanisms of chemical carcinogenesis. In: Moossa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology. Baltimore: Williams and Wilkins, 1991:31-7.
158. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogens and endometrial carcinoma. N Eng J Med 1975;293:1164-7.
159. Snijders MP, de Goeij AF, Koudstaal J, Rousch MJ, Scheres HM, Stoot JE, Bosman FT. Is immunohistochemical analysis of oestrogen and progesterone receptors in endometrial carcinoma superior to the radioligand binding assay? J Pathol 1990,161:129-35.
160. Soper JT, McCarty KS Jr, Creasman WT, McCarty KS Sr. Histologic control of biochemical steroid receptor analysis in endometrial carcinomas. Am J Obstet Gynecol 1985;153:520-3.
161. Soper JT, Segreti EM, Novotny DB, Mutch D, Creasman WT, McCarty KS Jr. Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis. Gynecol Oncol 1990;36:363-8.
162. Spona J, Ulm R, Bieglmayer C, Husslein P. Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma. Gynecol Obstet Invest 1979;10:71-80.
163. Strathy JH, Coulam CB, Spelsberg TC. Comparison of estrogen receptors in human premenopausal and postmenopausal uteri: Indication of biologically inactive receptor in postmenopausal uteri. Am J Obstet Gynecol 1982;142:372-82.
164. Thjissen JHH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989;25:1953-9.
165. Thornton JG, Wells M. Oestrogen receptor in glands and stroma of normal and neoplastic human endometrium: a combined biochemical, immunohistochemical, and morphometric study. J Clin Pathol 1987;40:1437-42.
166. Thorpe SM. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res Treatm 1987a;9:175-89.
167. Thorpe SM. Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: Greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res 1987b;47:6572-5.
168. Thorpe SM. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Cancer Res 1987c;47:1830-5.
169. Thorpe SM. Estrogen and progesterone receptor determination in breast cancer: technology, biology and clinical significance. Acta Oncol 1988;27:1-19.
170. Tsibris JCM, Cazenave CR, Cantor B, Notelowitz M, Kalra PS, Spellacy WN. Distribution of cytoplasmic estrogen and progesterone receptors in human endometrium. Am J Obstet Gynecol 1978;132:449-54.
171. Tsibris JC, Fort FL, Cazenave CR, Cantor B, Bardawil WA, Notelowitz M, Spellacy WN. The uneven distribution of estrogen and progesterone receptors in human endometrium. J Steroid Biochem 1981;14:997-1003.
172. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 1993;7:1256-65.
173. Underwood PB, Miller MC, Kreutner A. Endometrial carcinoma: The effect of estrogens. Gynecol Oncol 1979;8:60-73.
174. Utaaker E, Iversen OE, Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89-100.
175. Vecek N, Nola M, Marusic M, Ilic J, Babic D, Petrovecki M, Nikolic S, Marinovic S, Jukic D, Vecek N Jr. Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1994;73:730-3.
176. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244-55.
177. Vermeulen A, Verdonck L. Sex hormone concentration in postmenopausal women. Clin Endocrinol (Oxf) 1978;9:59-66.
178. Vihko R, Janne O, Kauppila A. Steroid receptors in normal, hyperplastic and malignant human endometrium. Ann Clin Res 1980;12:208-15.
179. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
180. Walter P, Green S, Greene G, Krust A, Bornert J-M, Jeltsch J-M, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985;82:7889-93.
181. Wanless C, Barker S, Puddefoot JR, Pahany C, Goode AW, Vinson GP, Phillips IR. Somatic change in the estrogen receptor gene associated with altered expression of the progesterone receptor. Anticanc Res 1991;11:139-42.
182. Wentz WB. Progestin therapy in endometrial hyperplasia. Gynecol Oncol
183. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD, O'Brien PC, Naessens JM. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990;162:418-26.